Literature DB >> 29174525

Clinical phenotypes and trajectories of disease progression in type 1 spinal muscular atrophy.

Roberto De Sanctis1, Marika Pane1, Giorgia Coratti2, Concetta Palermo1, Daniela Leone1, Maria Carmela Pera3, Emanuela Abiusi4, Stefania Fiori4, Nicola Forcina1, Lavinia Fanelli1, Simona Lucibello3, Elena S Mazzone1, Francesco Danilo Tiziano4, Eugenio Mercuri5.   

Abstract

The advent of clinical trials has highlighted the need for natural history studies reporting disease progression in type 1 spinal muscular atrophy. The aim of this study was to assess functional changes using the Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP INTEND) scale in a cohort of type 1 infants. Nutritional and respiratory longitudinal data were also recorded. Patients were classified according to the severity of the phenotype and age of onset. SMN2 copies were also assessed. Twenty patients were included, eight with early onset most severe phenotype, eight with the more typical type 1 phenotype and 4, who achieved some head control, with a milder phenotype. Both baseline values and trajectories of progression were different in the three subgroups (p = 0.0001). Infants with the most severe phenotype had the lowest scores (below 20) on their first assessment and had the most rapid decline. Those with the typical phenotype had scores generally between 20 and 40 and also had a fast decline. The infants with the milder phenotype had the highest scores, generally above 35, and a much slower deterioration. Infants with three SMN2 copies had an overall milder phenotype and milder progression while two SMN2 copies were found in all three subgroups.
Copyright © 2017. Published by Elsevier B.V.

Entities:  

Keywords:  Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders; Neuromuscular disorders; Outcome measures; Spinal Muscular Atrophy; Werdnig-Hoffman disease

Mesh:

Substances:

Year:  2017        PMID: 29174525     DOI: 10.1016/j.nmd.2017.09.015

Source DB:  PubMed          Journal:  Neuromuscul Disord        ISSN: 0960-8966            Impact factor:   4.296


  15 in total

1.  Motor neuron disease: A prospective natural history study of type 1 spinal muscular atrophy.

Authors:  Enrico Bertini; Eugenio Mercuri
Journal:  Nat Rev Neurol       Date:  2018-01-19       Impact factor: 42.937

Review 2.  Restoring Protein Expression in Neuromuscular Conditions: A Review Assessing the Current State of Exon Skipping/Inclusion and Gene Therapies for Duchenne Muscular Dystrophy and Spinal Muscular Atrophy.

Authors:  Omar Sheikh; Toshifumi Yokota
Journal:  BioDrugs       Date:  2021-06-07       Impact factor: 5.807

3.  An observational study of functional abilities in infants, children, and adults with type 1 SMA.

Authors:  Marika Pane; Concetta Palermo; Sonia Messina; Valeria A Sansone; Claudio Bruno; Michela Catteruccia; Maria Sframeli; Emilio Albamonte; Marina Pedemonte; Adele D'Amico; Giorgia Brigati; Roberto de Sanctis; Giorgia Coratti; Simona Lucibello; Enrico Bertini; Giuseppe Vita; Francesco Danilo Tiziano; Eugenio Mercuri
Journal:  Neurology       Date:  2018-07-25       Impact factor: 9.910

4.  Oral and Swallowing Abilities Tool (OrSAT) for Type 1 SMA Patients: Development of a New Module.

Authors:  Beatrice Berti; Lavinia Fanelli; Roberto de Sanctis; Roberta Onesimo; Concetta Palermo; Daniela Leone; Sara Carnicella; Giulia Norcia; Nicola Forcina; Giorgia Coratti; Valentina Giorgio; Antonella Cerchiari; Simona Lucibello; Richard Finkel; Marika Pane; Eugenio Mercuri
Journal:  J Neuromuscul Dis       Date:  2021

5.  Response to: Alfred Sandrock, Wildon Farwell. Letter to the Editor, Comparisons Between Separately Conducted Clinical Trials: Letter to the Editor Regarding Dabbous O, Maru B, Jansen JP, Lorenzi M, Cloutier M, Guérin A, et al. Adv Ther (2019) 36(5):1164-76. doi:10.1007/s12325-019-00923-8.

Authors:  Omar Dabbous; Benit Maru; Jeroen P Jansen; Maria Lorenzi; Martin Cloutier; Annie Guérin; Irina Pivneva; Eric Q Wu; Ramesh Arjunji; Douglas Feltner; Douglas M Sproule
Journal:  Adv Ther       Date:  2019-09-11       Impact factor: 3.845

6.  Survival, Motor Function, and Motor Milestones: Comparison of AVXS-101 Relative to Nusinersen for the Treatment of Infants with Spinal Muscular Atrophy Type 1.

Authors:  Omar Dabbous; Benit Maru; Jeroen P Jansen; Maria Lorenzi; Martin Cloutier; Annie Guérin; Irina Pivneva; Eric Q Wu; Ramesh Arjunji; Douglas Feltner; Douglas M Sproule
Journal:  Adv Ther       Date:  2019-03-16       Impact factor: 3.845

7.  An updated cost-utility model for onasemnogene abeparvovec (Zolgensma®) in spinal muscular atrophy type 1 patients and comparison with evaluation by the Institute for Clinical and Effectiveness Review (ICER).

Authors:  Rebecca Dean; Ivar Jensen; Phil Cyr; Beckley Miller; Benit Maru; Douglas M Sproule; Douglas E Feltner; Thomas Wiesner; Daniel C Malone; Matthias Bischof; Walter Toro; Omar Dabbous
Journal:  J Mark Access Health Policy       Date:  2021-02-28

8.  Spinal muscular atrophy within Amish and Mennonite populations: Ancestral haplotypes and natural history.

Authors:  Vincent J Carson; Erik G Puffenberger; Lauren E Bowser; Karlla W Brigatti; Millie Young; Dominika Korulczyk; Ashlin S Rodrigues; KaLynn K Loeven; Kevin A Strauss
Journal:  PLoS One       Date:  2018-09-06       Impact factor: 3.240

9.  Diagnostic journey in Spinal Muscular Atrophy: Is it still an odyssey?

Authors:  Maria Carmela Pera; Giorgia Coratti; Beatrice Berti; Adele D'Amico; Maria Sframeli; Emilio Albamonte; Roberto de Sanctis; Sonia Messina; Michela Catteruccia; Giorgia Brigati; Laura Antonaci; Simona Lucibello; Claudio Bruno; Valeria A Sansone; Enrico Bertini; Danilo Tiziano; Marika Pane; Eugenio Mercuri
Journal:  PLoS One       Date:  2020-03-23       Impact factor: 3.240

Review 10.  Longitudinal natural history of type I spinal muscular atrophy: a critical review.

Authors:  Eugenio Mercuri; Simona Lucibello; Marco Perulli; Giorgia Coratti; Roberto de Sanctis; Maria Carmela Pera; Marika Pane; Jacqueline Montes; Darryl C de Vivo; Basil T Darras; Stephen J Kolb; Richard S Finkel
Journal:  Orphanet J Rare Dis       Date:  2020-04-05       Impact factor: 4.123

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.